Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA

Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA

Abstract Background To date, triple-negative breast cancer (TNBC) treatment options are limited because of the loss of target receptors and, as a result, are only managed with chemotherapy. What is worse is that TNBC is frequently developing resistance to chemotherapy. By using small interfering RNA...

Full description

Bibliographic Details
Main Authors: Long Zhang, Chaofeng Mu, Tinghong Zhang, Dejun Yang, Chenou Wang, Qiong Chen, Lin Tang, Luhui Fan, Cong Liu, Jianliang Shen, Huaqiong Li
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Journal of Nanobiotechnology
Subjects:
RNA nanoparticles
XBP1
siRNA
TNBC
Chemoresistance
Online Access:https://doi.org/10.1186/s12951-020-00758-4

Internet

https://doi.org/10.1186/s12951-020-00758-4

Similar Items